Source: Financial Supervisory Service Data Analysis, Retrieval and Transfer System (DART) / 2026-05-06
Disclosure Type: Earnings Release (Preliminary Results) – Consolidated Financial Statements (Fair Disclosure)
💡 3-Second Summary
Celltrion’s preliminary consolidated financial results for Q1 2026 show strong growth year-on-year, with revenue and operating profit increasing by 36.00% and 115.41% to approximately KRW 1.14T and KRW 321.9B, respectively. However, compared to the immediate preceding quarter (Q4 2025), revenue dropped by 13.92% and operating profit decreased by 32.26%.
📊 1. [Key Disclosure Details & Major Figures Summary]
- Performance Period: January 1, 2026 ~ March 31, 2026 (Preliminary Q1 2026 figures)
- Revenue:
- Current Period: KRW 1,144,986,000,000 (Approx. KRW 1.14T)
- Quarter-on-Quarter (QoQ): 13.92% decrease (Preceding Quarter: KRW 1,330,157,000,000)
- Year-on-Year (YoY): 36.00% increase (Same Period Last Year: KRW 841,912,000,000)
- Operating Profit:
- Current Period: KRW 321,870,000,000 (Approx. KRW 321.9B)
- Quarter-on-Quarter (QoQ): 32.26% decrease (Preceding Quarter: KRW 475,172,000,000)
- Year-on-Year (YoY): 115.41% increase (Same Period Last Year: KRW 149,421,000,000)
- Profit Before Income Tax:
- Current Period: KRW 432,199,000,000 (Approx. KRW 432.2B)
- QoQ: 18.12% decrease / YoY: 121.09% increase
- Net Profit:
- Current Period: KRW 349,844,000,000 (Approx. KRW 349.8B)
- QoQ: 33.73% decrease / YoY: 222.93% increase
- Net Profit Attributable to Controlling Interest:
- Current Period: KRW 346,143,000,000 (Approx. KRW 346.1B)
- QoQ: 34.50% decrease / YoY: 218.54% increase
- Note: The official disclosure text does not state the specific drivers or operational reasons behind the performance fluctuations (the year-on-year expansion or the quarter-on-quarter decline). Furthermore, these figures are unaudited preliminary internal data prepared under K-IFRS and are subject to change during the formal review by external auditors.
📈 2. [Expert Perspective: What This Means for Investors]
- Pronounced Growth Expansion Compared to the Previous Year: The preliminary Q1 2026 performance displays a notable quantitative expansion when stacked against the same period of 2025. Revenue expanded by 36.00% and operating profit surged by 115.41%, indicating a substantial enhancement in absolute profitability over a 12-month trailing horizon. The sheer increase in the operating profit base to approximately KRW 321.9B stands out as a material fact.
- Sequential Moderation from the Preceding Quarter: In contrast to the robust year-on-year gains, a sequential softening occurred as revenue fell by 13.92% and operating profit contracted by 32.26% relative to Q4 2025. Because the filing itself does not delineate the causes of this sequential drop, investors should look to future full quarterly reports and company IR materials to evaluate whether this represents routine Q1 biopharma seasonality or transitory cost elements.
- Inherent Volatility in Unaudited Metrics: As explicitly flagged in the filing, these preliminary metrics are provided for convenience and remain subject to accounting adjustments. Given the sequential net profit decline of 33.73%, investors must manage expectations regarding potential variance between these provisional figures and the upcoming audited final quarterly results.
📝 Editor’s Comment (by K-STOCK Editor)
Applied Comment Style: Cautionary View
This preliminary report showcases a divergent trend: remarkable growth on a year-on-year basis coupled with a noticeable contraction compared to the preceding quarter. Crucially, the official document leaves the precise operational variables or expenses responsible for this sequential dip unexplained. Consequently, market participants should avoid speculative assertions or premature structural conclusions. The objective course of action is to await the final audited values and closely cross-examine the official quarterly report to discern whether this quarter-on-quarter drop signifies a temporary pause or a trend that requires longer-term monitoring.
📢 Disclaimer & Sources
Source: This content has been newly structured and written based on official data submitted to the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).
Investment Risk Warning: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright-related requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
